在COMMENCE试验的中期结果,该试验研究了使用生物假体与新型组织的 mitra 置换
David A Heimansohn1, Craig Baker2, Evelio Rodriguez3
1St Vincent The Heart Center of Indiana, Indianapolis, Ind.
JTCVS open
|October 9, 2023
概括
使用RESILIA组织的生物假体中关置换显示了良好的安全性和稳定的血液动力学功能超过五年. 这项研究强调了RESILIA组织在持久心脏门置换方面的潜力.
科学领域:
- 心血管外科心血管外科
- 生物材料科学 生物材料科学
- 医疗器械 医疗器械
背景情况:
- 生物假体心脏门对于治疗心脏膜疾病至关重要.
- 耐用性仍然是当前生物假体门的一个关键挑战.
- 雷西利亚组织是一种新型材料,旨在增强生物假体门的寿命.
研究的目的:
- 通过使用RESILIA组织,评估生物假体中枢替换术的中期安全性和血液动力学性能.
- 为了评估 RESILIA 组织生物假体在 mitra 位置的耐用性.
- 报告从未来的COMMENCE试验中关节队列的结果.
主要方法:
- 一个前性,单臂临床试验,涉及成年患者进行中枢置换.
- 在美国和加拿大的17个地点招募了82名患者.
- 安全事件的独立判断和血液动力学性能的心声回声评估.
主要成果:
- 所有原因的死亡率,结构膜恶化和重新手术的五年无事件概率分别为79.9%,98.7%和97.1%.
- 在5年的随访期间,血液动力学门功能保持稳定.
- 观察到罕见且主要是轻微/微不足道的门泄漏.
结论:
- 用RESILIA组织生物假体替换中枢门显示了有利的安全性.
- 在5年内观察到临床稳定的血液动力学性能.
- 瑞西利亚组织生物假体代表了持久的米特拉置换的有希望的选择.
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
20
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
20
Mitral Valve Prolapse I: Introduction
21
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
21
Mitral Regurgitation III: Medical Management
18
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
18
Mitral Stenosis III: Medical Management
12
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12
Mitral Stenosis I: Introduction
15
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
15
Mitral Regurgitation I: Introduction
15
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
15


